KPCB, Sequoia Capital and TF Capital also participated in the round, which will help fund Zai Lab’s clinical development programs as well as its ongoing in-licensing efforts.
The company is focused on developing novel medicines in the therapeutic areas of oncology, autoimmune and anti-infective.
Qiming managing partner Nisa Leung said, “Zai Lab is the leading innovative drug development company in China today. Led by Dr. Samantha Du, Zai has an experienced management team with strong track record in China and globally.”
Earlier this year Qiming closed its fourth dollar-denominated China fund on $500m.
The firm already had about $1.1bn under management ahead of the final close of the latest fund.
Copyright © 2014 AltAssets